DeepMed Research

Nanfang Hospital Southern Medical University

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+

Not Applicable

Completed

Conditions: Acute Myeloid Leukemia
Risk Stratification

Interventions: Other: Consolidation with auto-HSCT or HLA-matched HSCT
Other: Consolidation with chemotherapy (CT) or autologous hematopoietic stem cell transplantation (auto-HSCT)
Other: allogeneic HSCT

First Posted Date: 2016-10-18

Last Posted Date: 2023-08-08

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 207

Registration Number: NCT02936089

Hyperbaric Oxygen Therapy Improves Outcome of Hypoxic-Ischemic Encephalopathy

Not Applicable

Conditions: Hypoxic-ischemic Encephalopathy

Interventions: Device: hyperbaric oxygen

First Posted Date: 2016-09-09

Last Posted Date: 2018-04-05

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 250

Registration Number: NCT02894866

Locations: 🇨🇳
The First Hospital of Jilin University, Jilin, Jilin, China
🇨🇳
Hunan Children's hospital, Changsha, Hunan, China
🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China

and more 7 locations

Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia

Conditions: Chronic Myeloid Leukemia

Interventions: Other: blood sampling

First Posted Date: 2016-08-30

Last Posted Date: 2016-08-30

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 100

Registration Number: NCT02883036

Locations: 🇨🇳
Department of hematology,Nanfang Hospital, Guangzhou, Guangdong, China

MRD-directed Therapy for Low-risk and Intermediate-risk AML.

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Minimal Residual Disease

Interventions: Combination Product: MRD-directed therapy

First Posted Date: 2016-08-17

Last Posted Date: 2020-03-04

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 743

Registration Number: NCT02870777

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Effect of Chemotherapy vs No Chemotherapy Pre-transplant to MDS Undergoing Allo-HSCT

Conditions: Myelodysplastic Syndrome
Chemotherapy

Interventions: Drug: Demethylation drug
Drug: Chemotherapy regimen

First Posted Date: 2016-08-01

Last Posted Date: 2017-12-08

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 250

Registration Number: NCT02850822

Locations: 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Virtual Hepatic Venous Pressure Gradient (vHVPG) With CT Angiography (CHESS1601)

Not Applicable

Completed

Conditions: Hypertension, Portal

Interventions: Procedure: HVPG measurement
Procedure: CTA
Procedure: Doppler ultrasound

First Posted Date: 2016-07-25

Last Posted Date: 2019-01-08

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 102

Registration Number: NCT02842697

Locations: 🇨🇳
Beijing 302 Hospital, Beijing, Beijing, China
🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
Beijing Shijitan Hospital, Beijing, Beijing, China

EFFORT Further Extension Study

Phase 4

Conditions: Hepatitis B, Chronic

Interventions: Other: off-treatment follow-up
Drug: Telbivudine
Drug: Adefovir dipivoxil

First Posted Date: 2016-07-07

Last Posted Date: 2016-07-07

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 130

Registration Number: NCT02826070

Locations: 🇨🇳
Beijing Ditan Hospital, Beijing, Beijing, China
🇨🇳
People's Hospital of Beijing University, Beijing, Beijing, China
🇨🇳
The Third Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

and more 17 locations

G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Phase 2

Completed

Conditions: Allogeneic Hematopoietic Stem Cell Transplantation
Myelodysplastic Syndrome
Conditioning

Interventions: Drug: Decitabine
Drug: Busulfan (BU)
Drug: Cyclophosphamide (CY)
Drug: Granulocyte Colony-Stimulating Factor(G-CSF)

First Posted Date: 2016-04-20

Last Posted Date: 2022-02-14

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 202

Registration Number: NCT02744742

Locations: 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Multicenter Study on Suprapubic Catheterization Versus Transurethral Catheterization in Laparoscopic Surgery for Rectal Cancer

Not Applicable

Conditions: Surgery
Rectal Cancer

Interventions: Device: Transurethral catheterization using Foley catheter
Device: Suprapubic catheterization using central venous catheter(CVC-2 7F)

First Posted Date: 2016-04-05

Last Posted Date: 2018-04-26

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 120

Registration Number: NCT02728427

Locations: 🇨🇳
Fujian Provincial Hospital, Fuzhou, Fujian, China
🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
Fujian Provincial cancer Hospital, Fuzhou, Fujian, China

Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy

Phase 4

Completed

Conditions: Diabetic Nephropathies

Interventions: Drug: Exenatide
Drug: Lispro

First Posted Date: 2016-02-24

Last Posted Date: 2020-03-09

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 92

Registration Number: NCT02690883

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy